- ADC Bio secures additional equity round investment
- Tel Aviv, NU launch joint nanoscience programme
- Nashville Biosciences enters into agreement with BC Platforms
- J&J cleared of liability in talc cancer case by California jury
- Exscientia acquires Kinetic Discovery to build 'full stack' AI-driven drug discovery capabilities
- Diabetes claims have gone up over last two years
- Sandoz to focus on more lucrative markets
- 3-D study delivers first pre-clinical results on the toxicological impact of novel e-cigarette
- EDBI-backed Moderna Therapeutics files for $500M IPO
- Ping An Good Doctor, BDMS announce strategic cooperation
- YITU healthcare to use AI for cancer detection
- Grunenthal establishes commercial footprint in the US
- MindFi App makes mindfulness smart and measurable
- Angion Biomedica, Sinovant Sciences collaborate to develop BB3
-
Pharma | 05 January 2018 | News
AstraZeneca collaborates with Myriad Genetics for cancer therapy
AstraZeneca is working in collaboration with the molecular diagnostics firm Myriad Genetics’ for its tes...Read more
Digital Health | 05 January 2018 | News
Microsoft partners with Adaptive Biotechnologies
The tech giant Microsoft is partnering with Seattle biotech company Adaptive Biotechnologies on a year-long pr...Read more
-
World | 15 November 2018 | News
Sandoz to focus on more lucrative markets
Novartis’ Sandoz division recently announced that it was no longer pursuing US approval for Rixathon, it...Read more
-
World | 15 November 2018 | News
ADC Bio secures additional equity round investment
ADC Biotechnology (ADC Bio), announces that it has secured additional funding of £2.5 million from exist...Read more
-
Singapore | 14 November 2018 | News
MindFi App makes mindfulness smart and measurable
Singapore - MindFi, a Southeast Asian leader in digital wellness, has launched the third generation of its mob...Read more
-
Pharma | 04 January 2018 | News
Europe's biggest private biotech company raises $270 million
Europe’s largest privately held biotech company, Germany-based BioNTech, has raised $270 million to supp...Read more
South Korea – leading biosimilars opportunities for Asia
Historically, Asia has led in generics adoption and now, with more than 300 biosimilars under development, Asia is one of the leading regions for global biosimilars development. The foundations have been laid for the biosimilar industry in Korea, providing an opportunity for the region to become a global center for manufacturing and adoption of biosimilars in the next few decades. Just as Indian companies have carved out a leading position in the generic drug market, South Korean companies are poised to take leading positions in the biosimilars industry in the coming years.
